Navigation Links
FDA Approves New Multiple Sclerosis Drug
Date:3/28/2013

THURSDAY, March 28 (HealthDay News) -- A new drug called Tecfidera has been approved to treat adults with relapsing forms of multiple sclerosis, the U.S. Food and Drug Administration said Wednesday.

The approval is based on the results of two clinical trials showing that patients who took Tecfidera (dimethyl fumarate) capsules had fewer MS relapses than those who took an inactive placebo. One of the trials also showed that a worsening of MS-related disability occurred less often in patients who took the drug than in those who took the placebo.

"Tecfidera will be a welcome addition to the growing list of agents that alter the course of multiple sclerosis," said one expert, Dr. Fred Lublin, director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York City.

"Based on the clinical trial data available, this new agent has very impressive efficacy data and a good safety profile," he added.

The FDA said that Tecfidera may lower levels of white blood cells, which help protect the body from infection. Lower levels of white blood cells may increase the risk of infection, but no significant increase in infections occurred in patients taking the drug.

Before starting treatment with Tecfidera, and each year after, doctors should check patients' white blood cell counts, the FDA advised.

Flushing (warmth and redness), nausea, vomiting and diarrhea were the most common side effects in patients taking the drug, especially at the start of treatment with Tecfidera, which is made by Biogen Idec in Massachusetts.

"No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients," Dr. Russell Katz, director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Multiple sclerosis can impair movement, sensation and thinking, an
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Multiple Sclerosis Drug
(Date:9/2/2014)... pm EDT): In a Viewpoint published today in the ... team of Boston researchers call for the implementation of ... United States. The researchers from the Friedman School of ... and Boston Children,s Hospital write that policies taxing nearly ... help people make meaningful dietary changes and substantially reduce ...
(Date:9/2/2014)... TCG, a leading government technology strategy and IT consultancy, ... fastest-growing companies in America for the seventh year in a ... in 2013, 2012, 2011, 2010, 2009, 2008, and the Inc. ... 2010 to 2013, ranking the company at position 3,708 on ... up 635 spots from 2013! More information is on ...
(Date:9/2/2014)... The use of Xarelto (known generically ... at a rapid pace, even as Xarelto lawsuits ... the U.S., Bernstein Liebhard LLP reports. According to a ... a year of its 2011 launch, patients were just ... blood thinner that has been in use for several ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... September 2, 2014 In a large population-based ... found that mild cognitive impairment (MCI) occurred twice ... type 2. Interestingly, this strong association was only ... older participants (66-80 years) the association vanished. This ... Alzheimer,s Disease . , The concept of MCI ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2
... very practical agents in therapeutic applications. Researchers from ... Institute of Technology, writing Cancer Letters // (Available ... nanospheres as photothermal agent by selectively delivering gold ... a clinically related cancer biomarker, and discuss the ...
... true for the scientists who been working hard for the ... take an extra step ahead as it is likely to ... as their offspring, are safe to eat., ,Canada ... Canadian Scientists having proved themselves following the success regarding Starbuck, ...
... Publication, released on the 5th of October, which comprises ... has a comprehensive report on the threat of chronic ... Union Health Minister Dr Anbumani Ramadoss, the need to ... of chronic diseases in India was highlighted, stating that ...
... Sanofi Pasteur and Merck and found to be effective ... doses over 6 months which has shown 100% successful. The company ... protects against Human Papilloma virus infection and also genital warts, which ... market early next year and the profits would be great, and ...
... to regularly floss your teeth or so your dentist tells ... larger percentage of the population does not indulge in flossing. ... leads to gum problems including bleeding gums, receding gums and ... American Dental Association's (ADA) annual conference in Philadelphia says that ...
... for breast cancer patients, who show positive for Her-2/neu. ... positive, and they have a more resistant and active ... are Her-2/neu positive and the treatment for these patients ... not show any significant disease reduction. These patients should ...
Cached Medicine News:Health News:Gold Nanoparticles: Agents For Noninvasive Cancer Therapy 2Health News:Strategies to prevent the rising tide of the epidemic of chronic diseases 2Health News:Gardasil vaccine for cervical cancer 2
(Date:9/2/2014)... According to the new market research report ... Material (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... by MarketsandMarkets, the Chiral Chromatography Columns Market was valued ... at a CAGR of 5.2% from 2013 to reach ... market data tables and 15 figures spread through 135 ...
(Date:9/2/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... the company at the Morgan Stanley Global Healthcare Conference in ... date: Tuesday September 9, 2014 , Presentation time: 5:15 ... 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on ...
(Date:9/2/2014)... 2014  EMD Serono, Inc., a subsidiary of Merck ... that Drew Young has joined the company ... capacity, he will be responsible for leading the strategic ... future products.   Bringing more than 20 years ... efforts at pharmaceutical and biotech companies, Mr. Young comes ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... that a new market research report is available in ... Drug Delivery System http://www.reportlinker.com/p0337136/Chinese-Markets-for--Drug-Delivery-System.html ... System has grown at a fast pace in the ... and demand will continue to grow. This new study ...
... 9, 2010 Reportlinker.com announces that ... catalogue: Prostate Cancer - Italy Drug ... http://www.reportlinker.com/p0332355/Prostate-Cancer---Italy-Drug-Forecasts-and-Treatment-Analysis-to-2020.html Prostate Cancer - Italy ... SummaryGlobalData,s pharmaceutical report, "Prostate Cancer - Italy Drug ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Drug Delivery System 2Reportlinker Adds Chinese Markets for Drug Delivery System 3Reportlinker Adds Chinese Markets for Drug Delivery System 4Reportlinker Adds Chinese Markets for Drug Delivery System 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 14
Two prong stainless steel tips; with titanium handle/...
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Medicine Products: